# rheumatoid arthritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/rheumatoid-arthritis

> 15 upcoming FDA catalysts in rheumatoid arthritis: JADE-002 (JBIO) on 2027 (interim data readout); natrunix 400 mg (XBIT) on Jan to Apr 2027 (topline data readout); natrunix 400 mg (XBIT) on January 2027 (primary completion); lutikizumab (ABBV) on February 2027 (primary completion); and 11 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for rheumatoid arthritis?

15 upcoming FDA catalysts in rheumatoid arthritis: JADE-002 (JBIO) on 2027 (interim data readout); natrunix 400 mg (XBIT) on Jan to Apr 2027 (topline data readout); natrunix 400 mg (XBIT) on January 2027 (primary completion); lutikizumab (ABBV) on February 2027 (primary completion); and 11 more. Press release filed with the SEC (EX-99): "JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027" [Calendar and source filings](https://sec-api.dev/indications/rheumatoid-arthritis)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-094967, https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/d69373dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-13. Cite: https://sec-api.dev/indications/rheumatoid-arthritis#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q2 2025 | [CLN-978 trial start](https://sec-api.dev/pdufa/cln-978) | CGEM | rheumatoid arthritis | scheduled | "In the second quarter of 2025, we plan to initiate a company-sponsored Phase 1 clinical trial to evaluate CLN-978 in patients with rheumatoid arthritis ("RA"), designed and executed in collaboration with the Friedrich-Alexander University of Erlangen-Nuremberg and Università Cattolica del Sacro Cuore, Rome." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm)) |
| June 18, 2025 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Rheumatoid Arthritis | completed | "NCT06073093 (A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-18 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06073093)) |
| November 10, 2025 | [LY3541860 primary completion](https://sec-api.dev/pdufa/ly3541860) | LLY | Rheumatoid Arthritis | withdrawn | "NCT06859294 (A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06859294)) |
| December 8, 2025 | [LY3871801 primary completion](https://sec-api.dev/pdufa/ly3871801) | LLY | Rheumatoid Arthritis | completed | "NCT05848258 (An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05848258)) |
| Q2 2026 | [JADE-002 trial start](https://sec-api.dev/pdufa/jade201) | JBIO | rheumatoid arthritis | scheduled | "The company expects to initiate a Phase 1 clinical trial evaluating JADE201 in patients with rheumatoid arthritis in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/d108669dex991.htm)) |
| May 12, 2026 | [BGB-45035 primary completion](https://sec-api.dev/pdufa/bgb-45035) | ONC | Rheumatoid Arthritis | withdrawn | "NCT07100938 (A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-12 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100938)) |
| July 15, 2026 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | completed | "NCT05814627 (Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05814627)) |
| August 10, 2026 | [JADE-002 trial start](https://sec-api.dev/pdufa/jade201) | JBIO | rheumatoid arthritis | completed | "Announced dosing began in the Phase 1 clinical trial evaluating JADE201 in participants with rheumatoid arthritis; interim, biomarker-rich data expected in 2027 are anticipated to inform indication prioritization and a focused clinical development strategy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629dex991.htm)) |
| 2027 | [JADE-002 interim data readout](https://sec-api.dev/pdufa/jade201) | JBIO | rheumatoid arthritis | scheduled | "JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/d69373dex991.htm)) |
| Jan to Apr 2027 | [Natrunix 400 mg topline data readout](https://sec-api.dev/pdufa/natrunix) | XBIT | Rheumatoid Arthritis | scheduled | "NCT06590090 (Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor XBiotech, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06590090)) |
| January 2027 | [Natrunix 400 mg primary completion](https://sec-api.dev/pdufa/natrunix) | XBIT | Rheumatoid Arthritis | scheduled | "NCT06590090 (Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor XBiotech, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06590090)) |
| February 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Rheumatoid Arthritis | scheduled | "NCT06972446 (A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972446)) |
| Feb to May 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Rheumatoid Arthritis | scheduled | "NCT06972446 (A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972446)) |
| September 2027 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Rheumatoid Arthritis | scheduled | "NCT06754462 (A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06754462)) |
| Sep to Dec 2027 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Rheumatoid Arthritis | scheduled | "NCT06754462 (A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06754462)) |
| Sep to Dec 2027 | [PTC844 topline data readout](https://sec-api.dev/pdufa/ptc844) | PTCT | Rheumatoid Arthritis | scheduled | "NCT07779616 (Study of PTC844 in Participants With Active Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07779616)) |
| September 2027 | [PTC844 primary completion](https://sec-api.dev/pdufa/ptc844) | PTCT | Rheumatoid Arthritis | scheduled | "NCT07779616 (Study of PTC844 in Participants With Active Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07779616)) |
| Oct 2027 to Jan 2028 | [MK-8690 topline data readout](https://sec-api.dev/pdufa/mk-8690) | MRK | Rheumatoid Arthritis | scheduled | "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07895524)) |
| October 2027 | [MK-8690 primary completion](https://sec-api.dev/pdufa/mk-8690) | MRK | Rheumatoid Arthritis | scheduled | "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07895524)) |
| Nov 2027 to Feb 2028 | [AZD1163 topline data readout](https://sec-api.dev/pdufa/azd1163) | AZN | Rheumatoid Arthritis | scheduled | "NCT07276581 (A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276581)) |
| November 2027 | [AZD1163 primary completion](https://sec-api.dev/pdufa/azd1163) | AZN | Rheumatoid Arthritis | scheduled | "NCT07276581 (A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-12 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276581)) |
| July 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | scheduled | "NCT07904754 (Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07904754)) |
| Jul to Oct 2029 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | scheduled | "NCT07904754 (Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07904754)) |

## Drugs

- [CLN-978](https://sec-api.dev/pdufa/cln-978) (CGEM)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [LY3871801](https://sec-api.dev/pdufa/ly3871801) (LLY)
- [JADE-002](https://sec-api.dev/pdufa/jade201) (JBIO)
- [BGB-45035](https://sec-api.dev/pdufa/bgb-45035) (ONC)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Natrunix 400 mg](https://sec-api.dev/pdufa/natrunix) (XBIT)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [PTC844](https://sec-api.dev/pdufa/ptc844) (PTCT)
- [MK-8690](https://sec-api.dev/pdufa/mk-8690) (MRK)
- [AZD1163](https://sec-api.dev/pdufa/azd1163) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/rheumatoid-arthritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "rheumatoid arthritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/rheumatoid-arthritis

```bibtex
@misc{secapidev_indications_rheumatoid_arthritis_20261116,
  title        = {rheumatoid arthritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/rheumatoid-arthritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_rheumatoid_arthritis_20261116","title":"rheumatoid arthritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/rheumatoid-arthritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
